Samuel C Wassmer Selected Research

Cerebral Malaria

10/2021	Brain Magnetic Resonance Imaging Reveals Different Courses of Disease in Pediatric and Adult Cerebral Malaria.
1/2021	Plasma levels of hsa-miR-3158-3p microRNA on admission correlate with MRI findings and predict outcome in cerebral malaria.
1/2021	Plasmodium falciparum erythrocyte membrane protein 1 variants induce cell swelling and disrupt the blood-brain barrier in cerebral malaria.
11/2020	Haplotype of RNASE 3 polymorphisms is associated with severe malaria in an Indian population.
1/2019	Malaria inflammation by xanthine oxidase-produced reactive oxygen species.
10/2016	Angiotensin receptors and β-catenin regulate brain endothelial integrity in malaria.
8/2013	Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children.
5/2013	A simple protocol for platelet-mediated clumping of Plasmodium falciparum-infected erythrocytes in a resource poor setting.
7/2006	Cell vesiculation and immunopathology: implications in cerebral malaria.
4/2006	[LMP-420, a new therapeutic approach for cerebral malaria?].

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Samuel C Wassmer Research Topics

Disease

11	Cerebral Malaria 10/2021 - 01/2006
7	Malaria 01/2021 - 01/2006
3	Inflammation (Inflammations) 01/2019 - 08/2013
1	Edema (Dropsy) 01/2022
1	Acute Kidney Injury (Acute Renal Failure) 01/2022
1	Hypoxia (Hypoxemia) 10/2021
1	Infections 01/2021
1	Brain Edema (Cerebral Edema) 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Parasitemia 01/2020
1	Coinfection 01/2020
1	Cerebral Hemorrhage 10/2016
1	Communicable Diseases (Infectious Diseases) 01/2016
1	Thrombosis (Thrombus) 08/2013

Drug/Important Bio-Agent (IBA)

2	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2020
2	Endothelial Protein C ReceptorIBA 01/2021 - 08/2013
1	CreatinineIBA 01/2022
1	Lipocalin-2IBA 10/2021
1	Plasmodium falciparum erythrocyte membrane protein 1IBA 01/2021
1	Eosinophil Cationic ProteinIBA 11/2020
1	Phenobarbital (Luminal)FDA Link 01/2020
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019
1	Xanthine OxidaseIBA 01/2019
1	EnzymesIBA 01/2019
1	CytokinesIBA 01/2019
1	Antimalarials (Antimalarial Agents)IBA 10/2016
1	Angiotensin IIIBA 10/2016
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 10/2016
1	CateninsIBA 10/2016
1	Glycophorins (Glycophorin C)IBA 01/2016
1	Blood Group Antigens (Blood Groups)IBA 01/2016
1	methylallyl trisulfide (MATS)IBA 01/2016
1	C-Reactive ProteinIBA 02/2014
1	Protein CIBA 08/2013
1	ThrombomodulinIBA 08/2013
1	AnticoagulantsIBA 08/2013
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 05/2013
1	Biological ProductsIBA 07/2006
1	2- amino- 6- chloro- 9- ((5- dihydroxyboryl)pentyl)purineIBA 04/2006
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 01/2006

Therapy/Procedure

1	Therapeutics 10/2021
1	Nebulizers and Vaporizers (Inhaler) 01/2016